Fig. 2

CMH protects against loss of vascular integrity during EAE progression. a and d. Frozen sections of lumbar spinal cord taken from disease-free, EAE-normoxia or EAE-CMH mice at the peak symptomatic phase of EAE were stained for CD31 (AlexaFluor-488) and fibrinogen (Fbg) (Cy-3) in panel A (Scale bar = 500 μm) or CD31 (AlexaFluor-488) and MECA-32 (Cy-3) in panel D (Scale bar = 100 μm). b and e. Quantification of fibrinogen leakage (b) and MECA-32 expression (e). Results are expressed as the mean ± SEM (n = 6 mice/group). c and f. High power images of CD31/fibrinogen (c) and CD31/MECA-32 (f). Scale bar = 25 μm. Note that CMH markedly suppressed fibrinogen leakage as well as expression of MECA-32. ** p < 0.01